Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-07-01
|
| Series: | European Urology Open Science |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168320331591 |
| id |
doaj-ac49e495abb4422b9063f4f0cdd89d46 |
|---|---|
| record_format |
Article |
| spelling |
doaj-ac49e495abb4422b9063f4f0cdd89d462020-12-30T04:15:47ZengElsevierEuropean Urology Open Science2666-16832020-07-0119e863e864Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosisA.S. BjartellD. YeN. AgarwalB.H. ChungR. GivenA. MerseburgerM. ÖzgüroğluA. Juárez SotoH. UemuraA. Lopez-GitlitzG. LiS. Mc CarthyK.N. ChiS. Chowdhuryhttp://www.sciencedirect.com/science/article/pii/S2666168320331591 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
A.S. Bjartell D. Ye N. Agarwal B.H. Chung R. Given A. Merseburger M. Özgüroğlu A. Juárez Soto H. Uemura A. Lopez-Gitlitz G. Li S. Mc Carthy K.N. Chi S. Chowdhury |
| spellingShingle |
A.S. Bjartell D. Ye N. Agarwal B.H. Chung R. Given A. Merseburger M. Özgüroğlu A. Juárez Soto H. Uemura A. Lopez-Gitlitz G. Li S. Mc Carthy K.N. Chi S. Chowdhury Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis European Urology Open Science |
| author_facet |
A.S. Bjartell D. Ye N. Agarwal B.H. Chung R. Given A. Merseburger M. Özgüroğlu A. Juárez Soto H. Uemura A. Lopez-Gitlitz G. Li S. Mc Carthy K.N. Chi S. Chowdhury |
| author_sort |
A.S. Bjartell |
| title |
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis |
| title_short |
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis |
| title_full |
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis |
| title_fullStr |
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis |
| title_full_unstemmed |
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis |
| title_sort |
apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc) in titan: outcomes in patients (pts) with de novo (d1) mcspc vs. progression to mcspc after localized disease (d0) at diagnosis |
| publisher |
Elsevier |
| series |
European Urology Open Science |
| issn |
2666-1683 |
| publishDate |
2020-07-01 |
| url |
http://www.sciencedirect.com/science/article/pii/S2666168320331591 |
| work_keys_str_mv |
AT asbjartell apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT dye apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT nagarwal apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT bhchung apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT rgiven apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT amerseburger apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT mozguroglu apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT ajuarezsoto apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT huemura apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT alopezgitlitz apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT gli apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT smccarthy apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT knchi apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis AT schowdhury apalutamideapaformetastaticcastrationsensitiveprostatecancermcspcintitanoutcomesinpatientsptswithdenovod1mcspcvsprogressiontomcspcafterlocalizeddiseased0atdiagnosis |
| _version_ |
1724366887559626752 |